The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Covaxin is not approved in the USA for any age group
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Resolv ER may remedy leading causes of blindness in adults
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Go-ahead for pivotal clinical trial which is expected to commence by March
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Subscribe To Our Newsletter & Stay Updated
